ORLANDO, Fla., June 1, 2011 /PRNewswire/ -- GeneLink Biosciences, Inc. (OTCBB: GNLK.OB, “the Company,” “GeneLink,” or “GeneLink Biosciences”), a leading consumer genomics biotech company, held its Scientific Advisory Board Meeting at Disney’s Contemporary Resort Convention Center in Orlando, Florida from May 20-22, 2011. GeneLink Biosciences hosted the three day meeting to focus on the Company’s growth strategy and the advances being made in genomics where GeneLink maintains its leadership position. The Company combines genetic science, wellness and customization to create distinctive and innovative consumer products.
The Company plans to launch two exciting new personalized consumer product lines in 2011. These include a large scale direct-to-consumer initiative featuring a new brand being launched with Robert P. Trussell, Jr., Founder and Vice-Chairman of Tempur-Pedic, Inc., and a specialized exclusive product line for aesthetic physicians under GeneLink’s Dermagenetics® brand. The product applications include skincare, nutritional supplements and weight management. Clinical trials are anticipated to begin this summer to support and further validate the Company’s new and existing product lines.
GeneLink brought together its top scientific experts, its Board of Directors, management team, and leaders of the Company’s new marketing and product teams to focus on the Company’s evolving expansion and the development of its newest product lines.
Dr. Bernard Kasten, Executive Chairman and CEO, led this unique multi-disciplinary gathering of scientists and business leaders and observed: “The interaction of these leaders is further defining the exciting path forward for the Company. Building on GeneLink’s pioneering heritage and expertise in the application of genomic testing to personalized wellness, the Company continues to secure its position as the recognized leader in this rapidly emerging discipline.”
GeneLink Biosciences welcomed two new Scientific Advisory Board members: Maggie Palazzolo, MS, Clinical Validation Protocol Expert and currently Project Manager, Informatics, Cincinnati Children’s Hospital Medical Center, and Stephanie May Heinrich, Genomicist. Ms. Heinrich, is currently a researcher with the Faculty of Medicine at the Institute for Human Genetics at Justus-Liebig University in Giessen, Germany, and is expected to join GeneLink’s corporate team later this year. The Company’s esteemed Scientific Advisory Board consists of experts in the fields of genetics, genomic research, medicine, pediatrics, nutrition, public health, neuroscience, clinical laboratory medicine, nuclear medicine and imaging, and quality assurance. Dr. Thomas McKnight, author and Weight Management Specialist, also contributed to the meeting. The Company anticipates further expansion of its Scientific Advisory Board in the near future.
A newly identified opportunity for GeneLink exists in obtaining public and private sector grants to further validate GeneLink’s science-based approach to wellness through the application of genetics to consumer products. Linda Kirwin, Grant Writing Specialist, participated in the meeting and will support GeneLink’s efforts in this area.
Dr. Robert Ricciardi, Chief Science Officer and Founder, shared his vision for the further advancement of GeneLink’s DNA SNP-based technologies by expanding the range of current testing applications and protocols: “Our desire is for GeneLink Biosciences to be known as the global premier personalized wellness company.”
About GeneLink Biosciences, Inc.:
GeneLink Biosciences is a 17-year old leading biosciences company specializing in consumer genomics. GeneLink’s patented technologies include proprietary DNA test assessments linked to personalized health, beauty and wellness applications and products. Its DNA assessments provide information that enables the customization of nutritional and skincare products designed and manufactured to fulfill each individual consumer’s wellness needs. For more information visit www.genelinkbio.com
This release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GeneLink disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.
SOURCE GeneLink Biosciences, Inc.
